Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy.

[1]  M. Sixt,et al.  Rapid leukocyte migration by integrin-independent flowing and squeezing , 2008, Nature.

[2]  D. Irvine,et al.  Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. , 2008, Seminars in immunology.

[3]  H. Ueno,et al.  Taming cancer by inducing immunity via dendritic cells , 2007, Immunological reviews.

[4]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[5]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[6]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[7]  Helen Y Wang,et al.  Regulatory T cells and cancer. , 2007, Current opinion in immunology.

[8]  M. Krummel,et al.  Surface-bound chemokines capture and prime T cells for synapse formation , 2006, Nature Immunology.

[9]  D. Irvine,et al.  Homeostatic Lymphoid Chemokines Synergize with Adhesion Ligands to Trigger T and B Lymphocyte Chemokinesis1 , 2006, The Journal of Immunology.

[10]  David J Mooney,et al.  Alginate hydrogels as biomaterials. , 2006, Macromolecular bioscience.

[11]  A. Proudfoot,et al.  The biological relevance of chemokine-proteoglycan interactions. , 2006, Biochemical Society transactions.

[12]  Z. Werb,et al.  HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 , 2006, BMC Biochemistry.

[13]  J. Lora,et al.  Differential expression of inflammatory chemokines by Th1‐ and Th2‐cell promoting dendritic cells: A role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation , 2005, Immunology and cell biology.

[14]  Hua Tang,et al.  Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. , 2005, Blood.

[15]  A. Trautmann,et al.  CC Chemokine Ligand 19 Secreted by Mature Dendritic Cells Increases Naive T Cell Scanning Behavior and Their Response to Rare Cognate Antigen , 2005, The Journal of Immunology.

[16]  David J Mooney,et al.  Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. , 2005, Biomaterials.

[17]  T. Banks,et al.  Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. , 2005, Immunity.

[18]  F. Nestle,et al.  Dendritic-cell-based therapeutic vaccination against cancer. , 2005, Current opinion in immunology.

[19]  L. Zitvogel,et al.  Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 , 2004, The Journal of Immunology.

[20]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[21]  W. Oyen,et al.  Analysis of dendritic cell trafficking using EGFP-transgenic mice. , 2003, Immunology letters.

[22]  K. Chamoto,et al.  A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. , 2003, International immunology.

[23]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W. Lu,et al.  Therapeutic dendritic-cell vaccine for simian AIDS , 2003, Nature Medicine.

[25]  J. Becker,et al.  Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. , 2002, The Journal of investigative dermatology.

[26]  D. Tough,et al.  Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. , 2002, Blood.

[27]  R. Hromas,et al.  Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. , 2002, The Journal of pharmacology and experimental therapeutics.

[28]  P. Chang,et al.  A novel approach to tumor suppression with microencapsulated recombinant cells. , 2002, Human gene therapy.

[29]  S. Rosenberg.  Progress in the development of immunotherapy for the treatment of patients with cancer , 2001, Journal of internal medicine.

[30]  R. Steinman,et al.  Active immunization against cancer with dendritic cells: The near future , 2001, International journal of cancer.

[31]  Q. Shang,et al.  Tissue-Engineered Bone Repair of Sheep Cranial Defects with Autologous Bone Marrow Stromal Cells , 2001, The Journal of craniofacial surgery.

[32]  D J Mooney,et al.  Injection molding of chondrocyte/alginate constructs in the shape of facial implants. , 2001, Journal of biomedical materials research.

[33]  Anthony Atala,et al.  Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.

[34]  B. Redman,et al.  Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. , 2001, Cancer research.

[35]  P. Friedl,et al.  The biology of cell locomotion within three-dimensional extracellular matrix , 2000, Cellular and Molecular Life Sciences CMLS.

[36]  In Greek,et al.  Alginate dressings in surgery and wound management - part 1 , 2000 .

[37]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[38]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[39]  Simon,et al.  Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection , 1999, Immunology.

[40]  J. Prieto,et al.  Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas , 1999, Gene Therapy.

[41]  M. Lotze,et al.  Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. , 1999, Cancer research.

[42]  W. Oyen,et al.  Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. , 1999, Cancer research.

[43]  Antonio Lanzavecchia,et al.  Distinct patterns and kinetics of chemokine production regulate dendritic cell function , 1999, European journal of immunology.

[44]  J. Cyster,et al.  Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells. , 1999, Science.

[45]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Adrian L. Smith,et al.  Antigen-pulsed CD8α+ Dendritic Cells Generate an Immune Response after Subcutaneous Injection without Homing to the Draining Lymph Node , 1999, The Journal of experimental medicine.

[47]  J. Timmerman,et al.  Dendritic cell vaccines for cancer immunotherapy. , 1999, Annual review of medicine.

[48]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[49]  N. Restifo,et al.  T cell–tumor cell: a fatal interaction? , 1998, Cancer Immunology, Immunotherapy.

[50]  I. Hermans,et al.  Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. , 1998, Cancer research.

[51]  K. Zänker,et al.  CD4+ T lymphocytes migrating in three‐dimensional collagen lattices lack focal adhesions and utilize β1 integrin‐independent strategies for polarization, interaction with collagen fibers and locomotion , 1998, European journal of immunology.

[52]  J. Cyster,et al.  Epstein-Barr Virus–induced Molecule 1 Ligand Chemokine Is Expressed by Dendritic Cells in Lymphoid Tissues and Strongly Attracts Naive T Cells and Activated B Cells , 1998, The Journal of experimental medicine.

[53]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[55]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[56]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[57]  D. Hanahan,et al.  Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. , 1996, The Journal of clinical investigation.

[58]  K. Smetana.  Cell biology of hydrogels. , 1993, Biomaterials.

[59]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[60]  S. Tonegawa,et al.  Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.